Critical Therapeutics to Present at the FBR 2006 Growth Investor Conference on June 1, 2006 in New York City.

LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, will present at the Friedman Billings Ramsey (FBR) 2006 Growth Investor Conference on June 1, 2006 at 9:45 AM from the Grand Hyatt New York hotel.

Frank Thomas, Chief Financial Officer and Senior Vice President of Finance and Treasurer, will provide an update on the Company's strategy, operations and development pipeline. A live and archived webcast of this presentation will be available by logging on to the "Investors" section of the Company's website, www.crtx.com, and clicking the link labeled "Webcasts & Presentations."

About Critical Therapeutics

Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor approved for marketing by the U.S. Food and Drug Administration. The Company's commercialization efforts for ZYFLO are carried out by its specialty sales force. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization. For more information, please visit www.crtx.com.